Oncoscience published this trending research perspective in Volume 9, 2022, entitled, "Altos Labs and the quest for immortality: but can we live longer right now?" by Dr. Mikhail V. Blagosklonny from Roswell Park Cancer Institute, Buffalo, NY. DOI - https://doi.org/10.18632/oncoscience.552 Corresponding author - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com Abstract Some visionaries prefer to dream of immortality rather than to actually live longer. Here I discuss how combining rapamycin with other modalities may let us live long enough to benefit from future discoveries in cellular reprogramming and what needs to be done at Altos Labs to make this happen. Press release - https://aging-us.com/news_room/altos-labs-quest-for-immortality Keywords - aging, longevity, lifespan, geroscience, rapalogs, gerostatics About Oncoscience Oncoscience's mission is to cover the rapidly growing field of cancer research. It’s aim is to focus on emergent topics not currently covered by other journals. Launched in 2014, Oncoscience is a peer-reviewed, traditional-style, bi-monthly journal with free access. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors. Please visit our website at http://www.Oncoscience.us and connect with us: Facebook - https://www.facebook.com/Oncoscience/ Twitter - https://twitter.com/OncoscienceJrnl LinkedIn - https://www.linkedin.com/company/oncoscience/ YouTube - https://www.youtube.com/oncoscience Oncoscience is published by Impact Journals, LLC: http://www.ImpactJournals.com Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM
Analytical TechniquesBiopharmaCell ScienceDrug Discovery